Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Helwan University, Ain Helwan, POB 11795, Cairo, Egypt.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Galala University, Attaka, 43713, Suez, Egypt.
Drug Deliv Transl Res. 2024 Jul;14(7):1909-1922. doi: 10.1007/s13346-023-01496-4. Epub 2024 Jan 7.
Febuxostat (FBX), a potent xanthine oxidase inhibitor, is widely used as a blood uric acid-reducing agent and has recently shown a promising repurposing outcome as an anti-cancer. FBX is known for its poor water solubility, which is the main cause of its weak oral bioavailability. In a previous study, we developed a binary system complex between FBX and sulfobutylether-β-cyclodextrin (SBE7-βCD) with improved dissolution behavior. The aim of the current study was to investigate the effect of incorporating a water-soluble polymer with a binary system forming a ternary one, on further enhancement of FBX solubility and dissolution rate. In vivo oral bioavailability was also studied using LC-MS/MS chromatography. The polymer screening study revealed a marked increment in the solubility of FBX with SBE7-βCD in the presence of 5% w/v polyethylene glycol (PEG 6000). In vitro release profile showed a significant increase in the dissolution rate of FBX from FBX ternary complex (FTC). Oral in vivo bioavailability of prepared FTC showed more than threefold enhancement in C value (17.05 ± 2.6 µg/mL) compared to pure FBX C value (5.013 ± 0.417 µg/mL) with 257% rise in bioavailability. In conclusion, the association of water-soluble polymers with FBX and SBE7-βCD system could significantly improve therapeutic applications of the drug.
非布司他(FBX)是一种有效的黄嘌呤氧化酶抑制剂,被广泛用作降血尿酸药物,最近在抗癌方面显示出有前途的再利用前景。FBX 的水溶性差,这是其口服生物利用度低的主要原因。在之前的研究中,我们开发了 FBX 与磺丁基醚-β-环糊精(SBE7-βCD)的二元体系复合物,改善了其溶解行为。本研究旨在探讨将水溶性聚合物与二元体系结合形成三元体系对进一步提高 FBX 溶解度和溶解速率的影响。还使用 LC-MS/MS 色谱法研究了体内口服生物利用度。聚合物筛选研究表明,在存在 5% w/v 聚乙二醇(PEG 6000)的情况下,FBX 与 SBE7-βCD 形成二元体系可显著提高 FBX 的溶解度。体外释放曲线表明,FBX 三元复合物(FTC)中 FBX 的溶解速率显著提高。与纯 FBX 的 C 值(5.013 ± 0.417 µg/mL)相比,制备的 FTC 的体内口服生物利用度提高了 3 倍以上(17.05 ± 2.6 µg/mL),生物利用度提高了 257%。综上所述,水溶性聚合物与 FBX 和 SBE7-βCD 系统的结合可显著改善药物的治疗应用。